Allen L. Cohn, MD | Medical Oncologist ...

Dr. Allen L. Cohn

Claim this profile

Rocky Mountain Cancer Centers

Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
36 drugs studied

About Allen L. Cohn

Education:

  • Obtained MD from the University of Colorado School of Medicine in 1986.
  • Completed Residency in Internal Medicine at the University of Colorado Health Sciences Center in 1989.
  • Finished Fellowship in Hematology/Oncology at the University of Colorado Health Sciences Center in 1992.

Experience:

  • Board-certified in Internal Medicine, Hematology, and Medical Oncology.
  • Associated with Rocky Mountain Cancer Centers.

Area of expertise

1Colorectal Cancer
Allen L. Cohn has run 6 trials for Colorectal Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Cancer
Allen L. Cohn has run 5 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.
Rocky Mountain Cancer Centers
Image of trial facility.
Rocky Mountain Cancer Centers-Midtown

Clinical Trials Allen L. Cohn is currently running

Image of trial facility.

Tucatinib + Trastuzumab + Chemotherapy

for Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Lutetium (177Lu) Vipivotide Tetraxetan

for Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Recruiting2 awards Phase 36 criteria

More about Allen L. Cohn

Clinical Trial Related3 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Allen L. Cohn has experience with
  • Nivolumab
  • Ipilimumab
  • Oxaliplatin
  • Bevacizumab
  • Fluorouracil
  • Cetuximab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Allen L. Cohn specialize in?
Is Allen L. Cohn currently recruiting for clinical trials?
Are there any treatments that Allen L. Cohn has studied deeply?
What is the best way to schedule an appointment with Allen L. Cohn?
What is the office address of Allen L. Cohn?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security